On August 21, Sinopharm Engineering and Dingkang (Wuhan) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Dingkang Biology") formally signed a strategic cooperation agreement. Secretary of the Party Committee of the National Pharmaceutical Engineering, director chen Jinhui, Wang Guowei, General Manager of Wuhan Company, Ding Kang Biological CEO Wei Jianzhong and Vice President Thomas Matthew Risko attended the signing ceremony, and the heads of relevant business sections of both parties participated in the witness.

This strategic cooperation aims to integrate the advantageous resources of both parties, focus on the field of biopharmaceutical engineering, and build a long-term, stable and efficient strategic partnership. Based on based on the principle of "complementary advantages, mutual benefit and win-win", the two sides will carry out all-round and in-depth cooperation to jointly promote the high-quality construction and development of biomedical engineering.

In the exchange session, the two sides conducted in-depth discussions on issues such as smart low-carbon parks and modular factories, and reached consensus in many fields. Relying on the rich experience of Sinopharm Engineering in engineering design and construction, as well as Dingkang Bio's deep understanding of biopharmaceutical process and production needs, the two parties will jointly explore the best application mode of modular factories in the biopharmaceutical field, and form a design, Complete solution from construction to operation.

The two parties stated that they will use this signing as a new starting point to promote the implementation of cooperation projects as soon as possible, actively respond to industry opportunities and challenges, and work together to help the biomedical industry achieve new breakthroughs and move to new heights. Through this strategic cooperation, the two parties are expected to form synergies in the field of biopharmaceutical engineering, promote technological innovation and industrial upgrading, and contribute more to the development of the biopharmaceutical industry in China and the world.

(Marketing Department)